CGON NASDAQ
CG Oncology, Inc. Common stock
1W: -12.2%
1M: -10.1%
3M: +14.7%
YTD: +51.5%
1Y: +148.9%
$65.52
+2.21 (+3.50%)
Weekly Expected Move ±5.9%
$59
$63
$67
$71
$75
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$5.6B
52W Range23.65-75.5
Volume650,460
Avg Volume1,209,974
Beta0.42
Dividend—
Analyst Ratings
Company Info
CEOArthur Kuan
Employees113
SectorHealthcare
IndustryBiotechnology
IPO Date2024-01-25
Websitecgoncology.com
400 Spectrum Center Drive
Irvine, DE
US
Irvine, DE
US
+1 949 354 1630
About CG Oncology, Inc. Common stock
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
Latest News
CG Oncology Analysts Boost Their Forecasts Following Q1 Earnings
CG Oncology, Inc. (CGON) Reports Q1 Loss, Tops Revenue Estimates
CG Oncology GAAP EPS of -$0.71, revenue of $1.08B
CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates
CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Mulay James | M-Exempt | 15,600 | $36.63 | 2026-04-17 |
| Mulay James | S-Sale | 15,600 | $73.01 | 2026-04-17 |
| Mulay James | M-Exempt | 15,600 | $36.63 | 2026-04-17 |
| Bellete Ambaw | A-Award | 107,508 | $67.68 | 2026-04-15 |
| Kasturi Vijay | A-Award | 79,216 | $67.68 | 2026-04-15 |